REVIEW article
Front. Neurol.
Sec. Headache and Neurogenic Pain
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1603758
Sex differences in the effects of calcitonin gene-related peptide (CGRP) signaling on migraine-like behavior in animal models: A narrative review
Provisionally accepted
- 1The University of Texas at Dallas, Richardson, United States
- 2Center for Advanced Pain Studies, School of Behavioral and Brain Sciences, The University of Texas at Dallas, Richardson, Texas, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Migraine is a common neurological disorder with a typical onset in adolescence or early adulthood. Migraine is three times more common in women than men, but the definitive cause underlying the observed disparity is not fully understood. Calcitonin gene-related peptide (CGRP) is a neuropeptide and potent vasodilator that is now clearly linked to migraine based on the efficacy of drugs targeting its signaling. While the efficacy and safety of drugs targeting CGRP are now well established, there is a shortage of studies exploring sex differences between CGRP and CGRP-based therapy related to migraine. This review evaluates the preclinical literature focusing on the effect of CGRP and inhibition of CGRP signaling on migraine-like behavior in male and female rodents. For this review, PubMed database was searched using the following terms: “CGRP AND Migraine AND animal models”. Papers were selected for review and risk of bias (RoB) assessment to evaluate the central question – What sex differences in CGRP signaling and migraine-like behavior are observed in rodents? CGRP itself induces pronociceptive effects in both male and female mice but when considering studies that directly compared male and females, there is a case for stronger overall effects in female rodents. Inhibition of CGRP signaling has a primarily antinociceptive effect in studies using only male or female rodents. We highlight that very few studies are conducted with adequate statistical power to measure sex differences within a single study and several studies pool mice across sexes. Given the known sex differences in the human condition, this pooling methodology may not be best practice for future studies involved CGRP in rodents. Overall, while there is clinical evidence suggesting therapeutics targeting CGRP could possibly have different gendered effects humans, more preclinical studies need to be conducted to understand sex differences in CGRP or CGRP antagonism in migraine-like behavior.
Keywords: CGRP, antagonists, sex differences, Headache, Migraine, rodent models
Received: 31 Mar 2025; Accepted: 02 Jun 2025.
Copyright: © 2025 Lewter, Arnold, Narosov, Dussor and Kolber. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Benedict Kolber, The University of Texas at Dallas, Richardson, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.